Corvus Pharmaceuticals, Inc. (CRVS) vs Rigel Pharmaceuticals, Inc. (RIGL)

A side-by-side comparison of Corvus Pharmaceuticals, Inc. and Rigel Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CRVS vs RIGL

growth of $100 · dividends reinvested · last 10y
CRVS -33.9% (-4.1%/yr)RIGL +30.2% (+2.7%/yr)RIGL compounded faster over this window
050100150Start $10020182020202220242026$66$130
CRVS RIGL

CRVS vs RIGL: by the numbers

  • •CRVS is the larger company ($888M vs $853M market cap).
  • •RIGL is profitable (116.30% net margin) while CRVS runs a net loss (0.00%).

Metrics side by side

Valuation

MetricCRVSRIGL
P/E ratioN/A2.83
Forward P/EN/A13.44
P/S ratioN/A3.08
P/B ratio3.942.01
EV / EBITDAN/A9.28
FCF yieldN/A9.31%

Profitability

MetricCRVSRIGL
Gross margin0.00%91.39%
Operating margin0.00%42.63%
Net margin0.00%116.30%
ROE-24.02%75.67%
ROIC-25.25%18.72%

Growth (annualized)

MetricCRVSRIGL
Revenue CAGR (5Y)N/A13.94%
Total return CAGR (5Y)17.88%6.25%

Frequently asked

Is CRVS or RIGL more profitable?
RIGL runs the higher net margin — CRVS at 0.00% versus RIGL at 116.30%.
How have CRVS and RIGL total returns compared?
Over the past 10 years, CRVS delivered -4.26% and RIGL delivered 1.77% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.